Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AKTX 
Akari Therapeutics PLC (AKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.53
1 Year Target Price $4.53
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.22% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.11M USD | Price to earnings Ratio - | 1Y Target Price 4.53 |
Price to earnings Ratio - | 1Y Target Price 4.53 | ||
Volume (30-day avg) 1 | Beta 0.36 | 52 Weeks Range 0.57 - 3.15 | Updated Date 10/17/2025 |
52 Weeks Range 0.57 - 3.15 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.56% | Return on Equity (TTM) -112.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 29288374 | Price to Sales(TTM) - |
Enterprise Value 29288374 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.06 | Shares Outstanding 32614731 | Shares Floating 11219467464 |
Shares Outstanding 32614731 | Shares Floating 11219467464 | ||
Percent Insiders 34.29 | Percent Institutions 1.73 |
Upturn AI SWOT
Akari Therapeutics PLC
Company Overview
History and Background
Akari Therapeutics PLC is a late-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. It was formerly known as Volution Immuno Pharmaceuticals S.A. and changed its name in June 2017. The company's lead product candidate is Nomacopan.
Core Business Areas
- Drug Development: Focuses on the discovery, development, and commercialization of novel therapies for autoimmune and inflammatory diseases, particularly targeting the complement system.
Leadership and Structure
The company has a board of directors and a management team led by a Chief Executive Officer. Specific details of the current leadership team structure should be retrieved from company's website or SEC filings.
Top Products and Market Share
Key Offerings
- Nomacopan (Coversin): A second-generation complement inhibitor targeting C5. Under development for treatment of bullous pemphigoid (BP) and thrombotic microangiopathies (TMA). Market share is currently near zero as the drug is not yet approved. Competitors in BP include corticosteroids and rituximab. Competitors in TMA include eculizumab and ravulizumab.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development. It is characterized by strict regulatory requirements, lengthy development timelines, and high risk of failure. Autoimmune and inflammatory diseases represent a substantial market.
Positioning
Akari Therapeutics PLC is positioned as a company developing novel complement inhibitors, specifically targeting C5. If approved, Nomacopan would be competitive in targeted indications. Their competitive advantage lies in potentially offering an improved safety profile or efficacy compared to existing therapies.
Total Addressable Market (TAM)
The TAM for bullous pemphigoid and thrombotic microangiopathies is estimated to be in the billions of dollars. Akari's market position depends on successful clinical trials and subsequent regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel C5 inhibitor (Nomacopan)
- Potential for improved safety profile
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- No currently marketed products
Opportunities
- Successful clinical trial results
- Regulatory approval of Nomacopan
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from existing therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- ALXN
- JNJ
- LLY
Competitive Landscape
Akari Therapeutics PLC faces intense competition from established pharmaceutical companies. Its success depends on demonstrating superior efficacy or safety of Nomacopan compared to existing therapies.
Growth Trajectory and Initiatives
Historical Growth: Akari Therapeutics PLC's growth has been primarily driven by clinical development milestones and financing activities.
Future Projections: Future projections are highly dependent on clinical trial results and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include ongoing clinical trials of Nomacopan in bullous pemphigoid and thrombotic microangiopathies.
Summary
Akari Therapeutics PLC is a clinical-stage biopharmaceutical company with potential, but also substantial risk. Their success hinges on the success of Nomacopan, and they need to overcome significant financial constraints to get Nomacopan to market. The stock is highly volatile due to the binary nature of clinical trial outcomes. Clinical trial failures would be a substantial set back for the company, while success could bring a large return.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Investment decisions should be made after consulting a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akari Therapeutics PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-09-21 | CEO, President & Director Mr. Abizer Gaslightwala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.akaritx.com |
Full time employees 8 | Website https://www.akaritx.com | ||
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.